(Q40847551)

24 September 2017

Prognosis of small cell lung cancer patients with diabetes treated with metformin (English)

1 reference

24 September 2017

1 reference

T Xu

1

1 reference

24 September 2017

G Liang

series ordinal

2

1 reference

24 September 2017

L Yang

series ordinal

3

1 reference

24 September 2017

F Zhang

series ordinal

4

1 reference

24 September 2017

11 June 2015

1 reference

Clinical and Translational Oncology

24 September 2017

1 reference

24 September 2017

17

1 reference

24 September 2017

10

1 reference

24 September 2017

819-824

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-015-1311-1

24 September 2017

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Small cell lung cancer: state of the art and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

21 January 2018

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Do variants associated with susceptibility to pancreatic cancer and type 2 diabetes reciprocally affect risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Type 2 diabetes mellitus and risk of oral cancer and precancerous lesions: a meta-analysis of observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Diabetes mellitus and risk of thyroid cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Survival of patients with stage IV lung cancer with diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Mixed small cell and non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Combined SCLC clinical and pathologic characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

The effect of metformin and thiazolidinedione use on lung cancer in diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Immune-mediated antitumor effect by type 2 diabetes drug, metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Molecular mechanism of action of metformin: old or new insights?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Metformin prevents tobacco carcinogen--induced lung tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1311-1

Combined small-cell and non-small-cell lung cancer

21 January 2018

1 reference

12 December 2020

Identification and verification of Hsp90-beta as a potential serum biomarker for lung cancer

1 reference

12 December 2020

Impact of type 2 diabetes mellitus on the prognosis of early stage triple-negative breast cancer in People's Republic of China

1 reference

12 December 2020

Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes

1 reference

12 December 2020

Small-cell lung cancer

1 reference

12 December 2020

Obesity and diabetes epidemics: cancer repercussions

1 reference

12 December 2020

Association between diabetes mellitus and adverse characteristics of breast cancer at presentation

1 reference

12 December 2020

Management of recurrent small cell lung cancer

1 reference

12 December 2020

10.1007/S12094-015-1311-1

Identifiers

DOI

1 reference

24 September 2017

1 reference